Prime Medicine Appoints Experienced Biotech CFO Svetlana Makhni Amidst Going Concern Warning
PRME has more than doubled off its 52-week low of $1.11.
Summary
Prime Medicine appointed Svetlana Makhni, an experienced biotech CFO, effective April 16, 2026, a key move as the company faces a "going concern" warning.
Key Events · Executive and Board Changes · PRME
-
New Chief Financial Officer Appointed
Svetlana Makhni was appointed as Chief Financial Officer and principal financial officer, effective April 16, 2026. She brings over 20 years of experience in biotechnology CFO roles and investment banking.
-
CEO Retains Principal Executive Role
Allan Reine, M.D. will step down as principal financial officer but will continue in his role as Chief Executive Officer and principal executive officer.
-
Compensation Package Detailed
Ms. Makhni's compensation includes an annual base salary of $495,000, a $40,000 sign-on bonus, a target annual bonus of 40% of her base salary, and stock options to purchase 900,000 shares (800,000 time-based, 100,000 milestone-based).
Analysis · PRME · Life Sciences
The appointment of Svetlana Makhni as Chief Financial Officer is a significant development for Prime Medicine, especially given the company's recent "going concern" warning. Ms. Makhni brings over 20 years of relevant experience, including multiple CFO roles in clinical-stage biotechnology companies and investment banking. Her expertise will be crucial in navigating the company's financial challenges and strategic initiatives, including the ongoing arbitration with Beam Therapeutics. This move signals a proactive effort by the company to strengthen its financial leadership during a critical period.
At the time of this filing, PRME was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $684.3M. The 52-week trading range was $1.11 to $6.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.